💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for AxoGen, Inc. (AXGN)
« Back to company indexAXGN Chatter Timeline
Stock Ticker for AXGN
Most Active Tweeters for AXGN
| User | Tweets |
|---|---|
| @invescent | 1 |
| @SismasStock | 1 |
| @StckPro | 1 |
| @Tickeron | 1 |
Recent Tweets for AXGN
 |
@SismasStock $AXGN waiting for Buy signal on AXGN with https://t.co/WNHrn3Pr7t https://t.co/V1pZzkOuQV January 25th 2022, 6:01pm |
 |
@invescent $AXGN Data indicates that the overall analyst sentiment for AXGN is neutral Simplify the way you research stocks… https://t.co/7TdcI94U6O January 25th 2022, 6:01am |
 |
@Tickeron $AXGN's Aroon indicator reaches into Uptrend on January 14, 2022. View odds for this and other indicators:… https://t.co/65U5iauxbH January 19th 2022, 3:01am |
 |
@StckPro $AXGN NEW ARTICLE : AxoGen (AXGN) Receives a Buy from JMP Securities https://t.co/VU0cUFZ4FD Get all the latest… https://t.co/HSn8yRrF3m January 13th 2022, 5:01pm |
 |
@MaiteMerenda $AXGN Almost ripe for a run Chart by https://t.co/t5kOjgsWN3 https://t.co/5ZkEAUcZS5 January 11th 2022, 4:01pm |
 |
@A1Syad $AXGN Awaiting Buy Signal. Chart by https://t.co/1MjnDHV7ua https://t.co/wSCScWzfDG January 11th 2022, 1:01pm |
 |
@newsfilterio Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021 $AXGN https://t.co/sDNuPriMcB January 11th 2022, 5:01am |
 |
@Ba4Saso $AXGN Bullish pattern building. Chart by https://t.co/z6vAd7dl0q https://t.co/sUO6qLpFSQ January 10th 2022, 8:01pm |
|
@SismasStock $AXGN waiting for Buy signal on AXGN with https://t.co/WNHrn3Pr7t https://t.co/nE2v7S5p0z January 10th 2022, 3:01pm |
 |
@ShogunTrade $AXGN Waiting for Buy Signal. Chart by https://t.co/6vnULU2sSf https://t.co/sNvMg7x13K January 10th 2022, 2:01pm |
 |
@shortablestocks $AXGN is short sale restricted for 2022-01-10. https://t.co/qKJcOuthXP January 10th 2022, 2:01pm |
 |
@investor_feed $AXGN 8-K Axogen (10 Jan, 7:14am) ? Results of Operations and Financial Condition; Regulation FD Disclosure… https://t.co/r6NIGJn3dM January 10th 2022, 12:01pm |
 |
@Market_Newswire $AXGN SEC Filing: 8-K Earnings Reg FD - Axogen, Inc. (0000805928) January 10 https://t.co/nKl9cSD1or January 10th 2022, 12:01pm |
 |
@StockNewsBot2 $AXGN Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021 https://t.co/cciqxlZHys January 10th 2022, 12:01pm |
 |
@stock_titan $AXGN Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021 https://t.co/ReRi7jihZe January 10th 2022, 12:01pm |
|
@Tickeron $AXGN enters an Uptrend because Momentum Indicator exceeded the 0 level on January 4, 2022. View odds for this and… https://t.co/2TIY8RFYjz January 9th 2022, 6:01am |
|
@SismasStock $AXGN waiting for Buy signal on AXGN with https://t.co/WNHrn3Pr7t https://t.co/EYxLPQw9Ay January 8th 2022, 3:01pm |
 |
@MiriamGoodwin17 $AXGN For a limited time,, we are opening our trading chatroom to the public. https://t.co/Nrdhge2gOP January 8th 2022, 2:01am |
 |
@Uncletrade1 $AXGN Waiting for Short signal on AXGN with https://t.co/a56bsndwqN https://t.co/c8KFQCdRTC January 7th 2022, 10:01pm |
 |
@SwingTradeBot 20 DMA Support today: $AXGN ... https://t.co/deOpbNqdR6 January 7th 2022, 7:01pm |
 |
@ShortAlgoKing $AXGN Monitoring for a buy entry with UltraAlgo. Get access to UltraAlgo for simplified Buy / Sell signals. Regi… https://t.co/GxlE2uyvDb January 7th 2022, 2:01pm |
|
@newsfilterio Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings $AXGN https://t.co/TxjmF6FryM January 5th 2022, 6:01am |
 |
@FlashAlert_me $AXGN [15s. delayed]: Issued Press Release on January 04, 07:00:00: Axogen to Participate at AAHS ASPN ASRM 2022 An… https://t.co/1QgUEafnk3 January 4th 2022, 12:01pm |
|
@StockNewsBot2 $AXGN Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings https://t.co/0HB39MeV3C January 4th 2022, 12:01pm |
|
@stock_titan $AXGN Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings https://t.co/r1HxpVUPBZ January 4th 2022, 12:01pm |
|
@invescent $AXGN Data indicates that the overall analyst sentiment for AXGN is bearish. Simplify the way you research stock… https://t.co/jFdCr9I1Zj January 4th 2022, 9:01am |
|
@Tickeron $AXGN's in Uptrend: Moving Average Convergence Divergence (MACD) Histogram just turned positive. View odds for this… https://t.co/vmAU6ooENe January 2nd 2022, 12:01pm |
|
@Tickeron $AXGN in -5.54% Downtrend, falling for three consecutive days on December 29, 2021. View odds for this and other in… https://t.co/3WvVCUfoaq January 1st 2022, 6:01pm |
 |
@DylanStanton007 $AXGN HAS ROOM TO GROW January 1st 2022, 2:01pm |
|
@Tickeron $AXGN in -5.54% Downtrend, declining for three consecutive days on December 29, 2021. View odds for this and other… https://t.co/ffo8EtfhBt December 31st 2021, 5:12am |
 |
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s CEO KAREN L. ZADEREJ: https://t.co/v3VEsr4IVX December 30th 2021, 2:12am |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s Chief R&D Officer ANGELO SCOPELIANOS: https://t.co/XBbpNa2KSv December 30th 2021, 12:12am |
|
@newsfilterio $17,064.48 of shares sold by Zaderej Karen L. (CEO), reported in a new form 4 filed with the SEC $AXGN https://t.co/7MxQseQz56 December 29th 2021, 11:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s Chief Human Resources Officer MARIA D. MARTINEZ: https://t.co/9lTA9kG33q December 29th 2021, 11:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Operations MICHAEL PATRICK DONOVAN: https://t.co/BefNFxIy7V December 29th 2021, 11:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s Chief Strategy and BD Officer ISABELLE BILLET: https://t.co/8Os4q86SSs December 29th 2021, 10:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Regulatory Affairs & Policy MARK LOUIS FRIEDMAN: https://t.co/a9MUje2C4Q December 29th 2021, 10:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s EVP & Chief Financial Officer PETER J MARIANI: https://t.co/vJGmE6MnFZ December 29th 2021, 10:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Peripheral Nerve Science ERICK WAYNE DEVINNEY: https://t.co/5ORH9YCNYt December 29th 2021, 9:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s EVP & Chief Financial Officer PETER J MARIANI: https://t.co/HORfmfFYSZ December 23rd 2021, 5:12am |
|
@newsfilterio $11,485.32 of shares sold by Zaderej Karen L. (CEO), reported in a new form 4 filed with the SEC $AXGN https://t.co/x3MjrOOk9b December 23rd 2021, 1:12am |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Peripheral Nerve Science ERICK WAYNE DEVINNEY: https://t.co/8IK9UYgwHy December 22nd 2021, 11:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Operations MICHAEL PATRICK DONOVAN: https://t.co/Gf6559ph34 December 22nd 2021, 9:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s VP Regulatory Affairs & Policy MARK LOUIS FRIEDMAN: https://t.co/C8sOW6EobB December 22nd 2021, 9:12pm |
|
@InsiderAlerts4U $AXGN: New Insider Filing on Axogen, Inc.'s CEO KAREN L. ZADEREJ: https://t.co/CEam0kREM4 December 22nd 2021, 9:12pm |
 |
@quantisnow $AXGN ? SEC Form 4: Devinney Erick Wayne converted options into 575 shares and covered exercise/tax liability with… https://t.co/5fzJPpW4xl December 22nd 2021, 9:12pm |
|
@invescent $AXGN Data indicates that the overall analyst sentiment for AXGN is neutral Simplify the way you research stocks… https://t.co/oj9QihQZlE December 22nd 2021, 7:12am |
|
@invescent $AXGN Data indicates that the overall analyst sentiment for AXGN is neutral Simplify the way you research stocks… https://t.co/52sqPlruqU December 21st 2021, 4:12pm |
|
@SismasStock $AXGN waiting for Buy signal on AXGN https://t.co/5wO4q8tFgr December 21st 2021, 2:12pm |
|
@shortablestocks $AXGN is short sale restricted for 2021-12-21. https://t.co/qKJcOuthXP December 21st 2021, 2:12pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?